Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Other solid neoplasm 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 15Carcinoma, Hepatocellular 13Urinary Bladder Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 9Neoplasms 8Carcinoma, Transitional Cell 8Stomach Neoplasms 7Neoplasm Metastasis 7Breast Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Carcinoma, Neuroendocrine 3Urethral Neoplasms 2Ureteral Neoplasms 2Turcot syndrome 2Solid Tumors 2Rectal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Glioma 2

Interventions

Cisplatin 11Gemcitabine 10Radiotherapy, Intensity-Modulated 6Capecitabine 6Drug Therapy 3Docetaxel 3toripalimab 2spartalizumab 2pembrolizumab 2nimotuzumab 2fludarabine 2atezolizumab 2Specimen Handling 2Platinum 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Fluorouracil 2Disulfides 2Cyclophosphamide 2Carboplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2tislelizumab 1sintilimab 1penpulimab 1olaparib 1fludarabine phosphate 1dehydroftorafur 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Nasopharyngeal Carcinoma × atezolizumab × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡